$SKYE

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE - Skye Bioscience (NASDAQ:SKYE)

LOS ANGELES, Nov. 27, 2025 ( GLOBE NEWSWIRE ) -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ( "Skye" or "the Company" ) ( NASDAQ:SKYE ) for violations of §§10 ( b ) and 20 ( a ) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated ...

Original reporting
Benzinga · Globe Newswire
Published Nov 27, 2025, 1:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 27, 2025, 1:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE - Skye Bioscience (NASDAQ:SKYE) — source image
Decision brief

The 30-second read

$SKYENeutralMed
01

Why it matters

Legal proceedings introduce uncertainty, possibly leading to short-term stock declines; long-term effects depend on legal outcomes and company response.

02

Market read

The legal issue is significant for investors in Skye Bioscience and may influence biotech sector sentiment; broader market impact is limited.

03

What to watch

Potential positive developments, such as settlement or dismissal, could mitigate negative impacts and lead to a recovery.

Timing: Immediate, as the news is recent and legal proceedings may develop quickly.

Background

Skye Bioscience is facing a class action lawsuit alleging securities violations, which could impact investor confidence and stock performance.

Company-level read

Ticker impact

$SKYENeutralMedium confidence
Context

The news pertains directly to Skye Bioscience, Inc., a NASDAQ-listed biotech company, and involves a legal issue that could impact its stock performance.

Expected impact

Potential short-term decline of 5-10% due to increased uncertainty; long-term impact uncertain pending legal resolution.

Evidence & confidence

Legal actions can cause volatility; however, the actual impact depends on the lawsuit's progression and company's response.

Market effects

The legal issue may raise concerns about regulatory compliance within the biotech sector, potentially affecting peer companies.

Limited to U.S. markets, given the company's listing and jurisdiction.

Minimal, as the news is specific to a U.S.-listed company and legal matter.

Counterpoint

Legal issues may be overblown if the lawsuit lacks merit; the stock could rebound if the company manages the situation effectively.

Key entities

  • Skye Bioscience, Inc.

    A biotech firm listed on NASDAQ involved in the lawsuit.

  • DJS Law Group

    Legal representatives handling the class action lawsuit.

Related articles

$SKYEMedAI 8/10

Skye Bioscience, Redx Pharma To Combine To Operate As Fibrx Therapeutics

Skye Bioscience (SKYE) and privately held Redx Pharma agreed to combine and form Fibrx Therapeutics, expected to trade on Nasdaq. The deal is slated to close in Q4 2026, led by Redx management. About $125M financing is planned. Lead asset RXC008 targets fibrotic Crohn’s, with Phase 2 topline expected H2 2028. SKYE trades at $0.54.

$SKYEHighAI 9/10

Skye Bioscience, Inc.: Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.

$MARAMed

Crypto Biz: Bitcoin ETFs Rebound as Crypto Miners Extend AI Pivot

A $116 million Coldcard hardware wallet exploit renewed scrutiny of self-custody as US spot Bitcoin ETFs saw about $1 billion in net inflows for the week, according to Bloomberg. Strategy CEO Phong Le said Strategy will resume Bitcoin accumulation later this year; Riot Platforms reported a 20-year $9 billion compute deal with Anthropic. Trump Media plans to revamp its crypto treasury after a $238 million Q2 net loss.

$NEEMed

NextEra Inks Final Deal, Gets $3.3B for 4.3

NextEra Energy (NYSE: NEE) said it signed definitive agreements with the U.S. Department of Commerce and Japan’s government for up to 10 GW of gas-fired generation in Pennsylvania and Texas. The initial funding tranche of $3.3 billion has been released, according to the company, to support the South Mon project.